

J M Bowen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7600539/publications.pdf>

Version: 2024-02-01

143
papers

8,287
citations

46918

47
h-index

51492

86
g-index

150
all docs

150
docs citations

150
times ranked

6954
citing authors

#	ARTICLE	IF	CITATIONS
1	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2014, 120, 1453-1461.	2.0	838
2	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2020, 126, 4423-4431.	2.0	540
3	The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. <i>Cancer Treatment Reviews</i> , 2007, 33, 448-460.	3.4	235
4	Systematic review of basic oral care for the management of oral mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 3165-3177.	1.0	194
5	Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 333-341.	1.0	193
6	Gastrointestinal Microflora and Mucins May Play a Critical Role in the Development of 5-Fluorouracil-Induced Gastrointestinal Mucositis. <i>Experimental Biology and Medicine</i> , 2009, 234, 430-441.	1.1	182
7	Characterisation of mucosal changes in the alimentary tract following administration of Irinotecan: implications for the pathobiology of mucositis. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 33-41.	1.1	179
8	Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 313-326.	1.0	177
9	Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 1095-1100.	1.4	165
10	VSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss. <i>Cancer Biology and Therapy</i> , 2007, 6, 1445-1450.	1.5	156
11	Faecal microflora and Î²-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. <i>Cancer Biology and Therapy</i> , 2008, 7, 1919-1925.	1.5	150
12	Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 239-251.	1.1	147
13	Serum levels of NF-Î²B and pro-inflammatory cytokines following administration of mucotoxic drugs. <i>Cancer Biology and Therapy</i> , 2008, 7, 1139-1145.	1.5	145
14	Emerging evidence on the pathobiology of mucositis. <i>Supportive Care in Cancer</i> , 2013, 21, 3233-3241.	1.0	145
15	Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 3191-3207.	1.0	137
16	Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. <i>International Journal of Experimental Pathology</i> , 2009, 90, 489-499.	0.6	131
17	Emerging evidence on the pathobiology of mucositis. <i>Supportive Care in Cancer</i> , 2013, 21, 2075-2083.	1.0	121
18	Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1208-1215.	0.9	120

#	ARTICLE	IF	CITATIONS
19	Effect of calcium and dairy foods in high protein, energy-restricted diets on weight loss and metabolic parameters in overweight adults. <i>International Journal of Obesity</i> , 2005, 29, 957-965.	1.6	118
20	Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1376-1386.	1.9	114
21	Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. <i>Supportive Care in Cancer</i> , 2013, 21, 327-332.	1.0	113
22	Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 343-355.	1.0	111
23	Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. <i>Supportive Care in Cancer</i> , 2006, 14, 713-731.	1.0	109
24	Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. <i>Radiation Oncology</i> , 2010, 5, 22.	1.2	109
25	Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. <i>International Journal of Cancer</i> , 2016, 139, 2635-2645.	2.3	108
26	The pathogenesis of mucositis: updated perspectives and emerging targets. <i>Supportive Care in Cancer</i> , 2019, 27, 4023-4033.	1.0	106
27	Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. <i>Supportive Care in Cancer</i> , 2013, 21, 1843-1852.	1.0	103
28	Chemotherapy-Induced Modifications to Gastrointestinal Microflora: Evidence and Implications of Change. <i>Current Drug Metabolism</i> , 2009, 10, 79-83.	0.7	96
29	Systematic review of natural agents for the management of oral mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 3209-3221.	1.0	95
30	Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 3179-3189.	1.0	95
31	Systematic review of amifostine for the management of oral mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 357-364.	1.0	89
32	Anti-Inflammatory Cytokines: Important Immunoregulatory Factors Contributing to Chemotherapy-Induced Gastrointestinal Mucositis. <i>Chemotherapy Research and Practice</i> , 2012, 2012, 1-11.	1.6	86
33	Nuclear factor κ B (NF κ B) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1295-1303.	0.4	82
34	Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review. <i>Oncologist</i> , 2011, 16, 432-444.	1.9	80
35	Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. <i>International Journal of Cancer</i> , 2005, 116, 464-470.	2.3	72
36	Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. <i>Pathology</i> , 2005, 37, 56-62.	0.3	70

#	ARTICLE	IF	CITATIONS
37	Irinotecan-induced mucositis is associated with changes in intestinal mucins. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 123-132.	1.1	70
38	Irinotecan disrupts tight junction proteins within the gut. <i>Cancer Biology and Therapy</i> , 2014, 15, 236-244.	1.5	67
39	Establishment of a Single-Dose Irinotecan Model of Gastrointestinal Mucositis. <i>Chemotherapy</i> , 2007, 53, 360-369.	0.8	61
40	A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor- κ B, COX-1, and COX-2. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2319-2327.	1.9	57
41	Animal Models of Mucositis: Implications for Therapy. <i>The Journal of Supportive Oncology</i> , 2011, 9, 161-168.	2.3	57
42	Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. <i>Experimental Biology and Medicine</i> , 2010, 235, 1244-1256.	1.1	55
43	ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis. <i>Cancer Treatment Reviews</i> , 2015, 41, 646-652.	3.4	53
44	Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 27-39.	1.1	53
45	Chemotherapy-induced mucosal barrier dysfunction. <i>Current Opinion in Supportive and Palliative Care</i> , 2013, 7, 155-161.	0.5	51
46	Mechanisms of TKI-induced diarrhea in cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2013, 7, 162-167.	0.5	51
47	Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. <i>Pharmacogenomics Journal</i> , 2017, 17, 21-28.	0.9	51
48	Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019, 27, 4011-4022.	1.0	51
49	Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 485-496.	1.4	51
50	Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 3223-3232.	1.0	50
51	The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy-induced gastrointestinal toxicity. <i>International Journal of Cancer</i> , 2019, 144, 2365-2376.	2.3	48
52	New thoughts on the pathobiology of regimen-related mucosal injury. <i>Supportive Care in Cancer</i> , 2006, 14, 516-518.	1.0	47
53	Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. <i>International Journal of Cancer</i> , 2007, 121, 1847-1856.	2.3	47
54	Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. <i>Clinical and Experimental Medicine</i> , 2005, 4, 188-195.	1.9	46

#	ARTICLE	IF	CITATIONS
55	Radiation therapy-induced mucositis: Relationships between fractionated radiation, NF- κ B, COX-1, and COX-2. <i>Cancer Treatment Reviews</i> , 2006, 32, 645-651.	3.4	44
56	Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 187-197.	0.5	43
57	Methodology for the MASCC/ISOO Mucositis Clinical Practice Guidelines Update. <i>Supportive Care in Cancer</i> , 2013, 21, 303-308.	1.0	42
58	Emerging drugs for chemotherapy-induced mucositis. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 511-522.	1.0	41
59	Biomarkers of regimen-related mucosal injury. <i>Cancer Treatment Reviews</i> , 2011, 37, 487-493.	3.4	41
60	Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. <i>Experimental Biology and Medicine</i> , 2007, 232, 96-106.	1.1	41
61	Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. <i>Supportive Care in Cancer</i> , 2020, 28, 5059-5073.	1.0	40
62	Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. <i>The Journal of Supportive Oncology</i> , 2007, 5, 259-67.	2.3	40
63	Irinotecan changes gene expression in the small intestine of the rat with breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 337-348.	1.1	38
64	TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2767-2779.	1.9	38
65	Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. <i>Gut Microbes</i> , 2021, 13, 1979878.	4.3	38
66	Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation. <i>Indian Journal of Gastroenterology</i> , 2021, 40, 5-21.	0.7	38
67	Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. <i>Pharmacogenomics</i> , 2016, 17, 435-451.	0.6	37
68	Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis?. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1-9.	1.1	35
69	Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 627-635.	1.1	35
70	TLR4/PKC ϵ -mediated tight junction modulation: A clinical marker of chemotherapy-induced gut toxicity?. <i>International Journal of Cancer</i> , 2014, 135, 2483-2492.	2.3	35
71	Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542092849.	0.8	35
72	Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. <i>International Journal of Experimental Pathology</i> , 2011, 92, 357-365.	0.6	34

#	ARTICLE	IF	CITATIONS
73	Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. <i>Cancer Biology and Therapy</i> , 2012, 13, 1269-1275.	1.5	34
74	Toll-like receptor 4 signaling: A common biological mechanism of regimen-related toxicities. <i>Cancer Treatment Reviews</i> , 2015, 41, 122-128.	3.4	34
75	MASCC/ISOO clinical practice guidelines for the management of mucositis: sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 3539-3562.	1.0	33
76	Advances in the understanding and management of mucositis during stem cell transplantation. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 341-346.	0.5	32
77	Development of the MASCC/ISOO Clinical Practice Guidelines for Mucositis: considerations underlying the process. <i>Supportive Care in Cancer</i> , 2013, 21, 309-312.	1.0	30
78	Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis. <i>Journal of Oral Pathology and Medicine</i> , 2015, 44, 459-467.	1.4	29
79	Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. <i>Investigational New Drugs</i> , 2009, 27, 173-178.	1.2	28
80	Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. <i>International Journal of Cancer</i> , 2017, 140, 2820-2829.	2.3	27
81	Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 617-627.	1.1	25
82	The microbiota-gut-brain axis: An emerging therapeutic target in chemotherapy-induced cognitive impairment. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 116, 470-479.	2.9	25
83	Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006, 2, 39-49.	0.7	24
84	Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. <i>Anti-Cancer Drugs</i> , 2007, 18, 197-210.	0.7	22
85	HER2 Targeted Therapies for Cancer and the Gastrointestinal Tract. <i>Current Drug Targets</i> , 2009, 10, 537-542.	1.0	22
86	Chemotherapy-induced gut toxicity and pain: involvement of TLRs. <i>Supportive Care in Cancer</i> , 2016, 24, 2251-2258.	1.0	22
87	Combined Systematic Review and Transcriptomic Analyses of Mammalian Aquaporin Classes 1 to 10 as Biomarkers and Prognostic Indicators in Diverse Cancers. <i>Cancers</i> , 2020, 12, 1911.	1.7	22
88	New Pathways for Alimentary Mucositis. <i>Journal of Oncology</i> , 2008, 2008, 1-7.	0.6	21
89	Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory disease. <i>Journal of Cellular Physiology</i> , 2021, 236, 877-888.	2.0	21
90	Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. <i>Supportive Care in Cancer</i> , 2015, 23, 1233-1236.	1.0	18

#	ARTICLE	IF	CITATIONS
91	Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer. <i>International Journal of Cancer</i> , 2018, 142, 369-380.	2.3	18
92	Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 31-37.	1.1	17
93	Oral-Gut Microbiome Axis in the Pathogenesis of Cancer Treatment-Induced Oral Mucositis. <i>Frontiers in Oral Health</i> , 2022, 3, 881949.	1.2	17
94	Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 1779-1788.	1.0	16
95	The application of cytokeratin-18 as a biomarker for drug-induced liver injury. <i>Archives of Toxicology</i> , 2021, 95, 3435-3448.	1.9	16
96	Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus. <i>World Journal of Gastroenterology</i> , 2020, 26, 2570-2583.	1.4	16
97	Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. <i>Journal of Controlled Release</i> , 2022, 341, 676-701.	4.8	16
98	Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. <i>Cancer Biology and Therapy</i> , 2007, 6, 541-547.	1.5	15
99	Technological advances in mucositis research: New insights and new issues. <i>Cancer Treatment Reviews</i> , 2008, 34, 476-482.	3.4	14
100	Fractionated abdominal irradiation induces intestinal microvascular changes in an in vivo model of radiotherapy-induced gut toxicity. <i>Supportive Care in Cancer</i> , 2017, 25, 1973-1983.	1.0	14
101	Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 233-249.	1.1	14
102	Colonic migrating motor complexes are inhibited in acute tri-nitro benzene sulphonic acid colitis. <i>PLoS ONE</i> , 2018, 13, e0199394.	1.1	14
103	The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 793-803.	1.1	14
104	Development of the Rat Model of Lapatinib-Induced Diarrhoea. <i>Scientifica</i> , 2014, 2014, 1-6.	0.6	13
105	New pharmacotherapy options for chemotherapy-induced alimentary mucositis. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 347-354.	1.4	13
106	What are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity?. <i>Future Oncology</i> , 2015, 11, 2367-2370.	1.1	13
107	Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 531-543.	1.1	13
108	Selection of Housekeeping Genes for Gene Expression Studies in a Rat Model of Irinotecan-Induced Mucositis. <i>Chemotherapy</i> , 2011, 57, 43-53.	0.8	12

#	ARTICLE	IF	CITATIONS
109	Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. <i>Toxicology</i> , 2010, 269, 1-12.	2.0	11
110	Investigation of Effect of Nutritional Drink on Chemotherapy-Induced Mucosal Injury and Tumor Growth in an Established Animal Model. <i>Nutrients</i> , 2013, 5, 3948-3963.	1.7	10
111	Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 431-434.	1.1	10
112	Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity. <i>Experimental Biology and Medicine</i> , 2019, 244, 1178-1185.	1.1	10
113	Acute Colitis Drives Tolerance by Persistently Altering the Epithelial Barrier and Innate and Adaptive Immunity. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1196-1207.	0.9	10
114	A novel <i>in vitro</i> platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. <i>Experimental Biology and Medicine</i> , 2016, 241, 1386-1394.	1.1	8
115	Patient preferences on the integration of complementary therapy with conventional cancer care. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e311-e318.	0.7	8
116	Amitriptyline prevents CPT-11-induced early-onset diarrhea and colonic apoptosis without reducing overall gastrointestinal damage in a rat model of mucositis. <i>Supportive Care in Cancer</i> , 2019, 27, 2313-2320.	1.0	8
117	Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines. <i>Biomedicines</i> , 2020, 8, 2.	1.4	8
118	Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation <i>in vivo</i> . <i>Supportive Care in Cancer</i> , 2018, 26, 3873-3882.	1.0	7
119	Antibiotic-Induced Gut Microbiota Depletion Accelerates the Recovery of Radiation-Induced Oral Mucositis in Rats. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 845-858.	0.4	7
120	Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. <i>Supportive Care in Cancer</i> , 2015, 23, 3165-3172.	1.0	6
121	Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 152-156.	0.5	6
122	Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF β 2), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity. <i>International Journal of Radiation Biology</i> , 2018, 94, 645-655.	1.0	6
123	Biomarkers of Small Intestinal Mucosal Damage Induced by Chemotherapy: An Emerging Role for the ¹³ C Sucrose Breath Test. <i>The Journal of Supportive Oncology</i> , 2012, 11, 61-7.	2.3	6
124	Do Serum Levels of Eosinophil Granule-derived Protein Change in Patients Undergoing Pelvic Radiotherapy?. <i>Clinical Oncology</i> , 2005, 17, 382-384.	0.6	5
125	Selective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat Model. <i>Chemotherapy</i> , 2018, 63, 284-292.	0.8	5
126	Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant. <i>Breast Cancer</i> , 2021, 28, 99-109.	1.3	5

#	ARTICLE	IF	CITATIONS
127	Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats. <i>Neoplasia</i> , 2022, 30, 100806.	2.3	5
128	Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study. <i>Supportive Care in Cancer</i> , 2017, 25, 391-398.	1.0	4
129	Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 217-236.	1.1	4
130	Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 199-209.	0.8	4
131	Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 275-281.	1.1	4
132	Prevention and Treatment of Regimen-Related Mucosal Toxicity. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008, 3, 68-75.	0.8	3
133	Routine assessment of the gut microbiome to promote preclinical research reproducibility and transparency. <i>Gut</i> , 2017, 66, 1869-1871.	6.1	3
134	Individual or combination treatments with lapatinib and paclitaxel cause potential bone loss and bone marrow adiposity in rats. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 4180-4191.	1.2	3
135	Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis. <i>Annals of Gastroenterology</i> , 2019, 32, 584-592.	0.4	2
136	Editorial Comment. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 155-156.	0.5	1
137	The science of mucositis. <i>Supportive Care in Cancer</i> , 2022, 30, 2915.	1.0	1
138	Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review. <i>BioMed Research International</i> , 2022, 2022, 1-13.	0.9	1
139	Use of Project Teams in Preclinical Development. , 0, , 65-79.		0
140	Relationship between Animal Models and Clinical Research: Using Mucositis as a Practical Example. , 0, , 81-108.		0
141	Mouth care protocol for oral mucositis. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 158-158.	0.5	0
142	Cancer treatment-related gastrointestinal symptoms. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 118-119.	0.5	0
143	Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0